Where these compounds stand legally, by jurisdiction. Pick your country in the top bar — every jurisdiction stays viewable, nothing is hidden. Educational only; not a sourcing guide.
Across AU/US/UK the common pattern: a small set of peptides are approved prescription medicines for specific indications; the large majority sold as 'research peptides' are unapproved, not for human use as labelled, and quality is unverified without independent testing.
Brief factual comparison so the AU content is not presented in isolation. Not jurisdiction-targeted.
Educational summary — verify against the primary regulator. Switch jurisdiction in the top bar to see others.
Regulator: Therapeutic Goods Administration (TGA), part of the Australian Government Department of Health and Aged Care.
Scheduling Framework:
Instrument: The Poisons Standard, also called the Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP).
Summary: Most peptides with pharmacological activity are classified Schedule 4 (Prescription Only Medicine) or higher. Some are Schedule 4 by class entry; others fall under broader entries (e.g. growth hormone secretagogues, hormones).
Schedules Relevant: {'schedule': 'Schedule 4 (S4)', 'meaning': 'Prescription Only Medicine. Requires a prescription from a registered Australian medical practitioner and dispensing by a licensed pharmacy.'}, {'schedule': 'Schedule 10 (S10)', 'meaning': 'Substances of such danger to health as to warrant prohibition of sale, supply and use (rare for peptides; relevant for some related compounds).'}, {'schedule': 'Unscheduled / cosmetic', 'meaning': 'Some topical cosmetic peptides (e.g. copper peptide, palmitoyl/acetyl cosmetic peptides) are permitted as cosmetic ingredients and are not S4 in that topical context.'}
Artg Status:
Principle: To be lawfully supplied as a therapeutic good in Australia, a product generally must be entered on the Australian Register of Therapeutic Goods (ARTG).
Most Research Peptides: Most peptides discussed in the wellness/research space (e.g. BPC-157, TB-500, CJC-1295, ipamorelin, epitalon, MOTS-c) are NOT ARTG-registered and are 'unapproved therapeutic goods'.
Approved Examples: GLP-1/GIP class drugs such as semaglutide and tirzepatide ARE ARTG-registered as branded prescription medicines (e.g. Ozempic, Wegovy, Rybelsus, Mounjaro). Grey-market 'research' versions are not the approved products.
Personal Importation Scheme:
What It Is: A pathway allowing an individual to import certain unapproved therapeutic goods from overseas for their own personal use (or for an immediate family member), subject to conditions.
Quantity Limit: The import must not exceed a 3-month supply at the maximum dose recommended (by prescription for prescription-only medicines, or by the manufacturer for non-prescription medicines).
Annual Limit: The total quantity imported within any 12-month period must not exceed a 15-month supply.
Prescription Requirement: For goods that are prescription-only (Schedule 4) in Australia, the importer must hold a valid Australian prescription or written authority issued by an Australian registered medical practitioner at the time of importation.
Not For Resale: Goods imported under the scheme are for personal use only and must not be sold or supplied to others.
Tga Caveat: The scheme does not assess the safety, quality or efficacy of imported products. The TGA explicitly warns that unapproved injectable peptide products may carry significant safety risks.
Source: https://www.tga.gov.au/products/unapproved-therapeutic-goods/access-pathways/personal-importation-scheme
Tga Safety Position On Peptides:
Stated Concern: The TGA has stated concern about the rise in import, supply, compounding and advertising of unapproved peptide products and the potential safety risks.
Injectable Risk: Unapproved peptide products, particularly those that are injected, can carry significant safety risks including contamination, infection or local tissue damage. Products identified only by codes, or that do not clearly state active ingredient, strength or dosage, pose particular risk.
Practitioner Obligations: Healthcare practitioners who compound, prescribe or supply unapproved peptide products must comply with all Commonwealth and state/territory legislation and professional standards, including those set by Ahpra.
Compounding Exemption: A compounded medicine is generally only exempt from ARTG inclusion when dispensed or extemporaneously compounded for a particular person for application to that person (or compounded in a hospital by a relevant pharmacist in anticipation of patient need). Bulk/anticipatory compounding of unapproved peptides for general supply is not covered.
Advertising Prohibition: Advertising of prescription-only (and most pharmacist-only) medicines to the public is prohibited unless authorised by an Australian government authority. Advertising unapproved therapeutic goods to the public is prohibited under Australian law; promoting such products online or via social media may constitute a breach.
Enforcement: The TGA undertakes compliance and enforcement action — including infringement notices — where unlawful import, compounding, supply or advertising of unapproved therapeutic goods is identified.
Source: https://www.tga.gov.au/safety/safety-monitoring-and-information/safety-alerts/understanding-your-responsibilities-when-importing-compounding-and-supplying-unapproved-peptide-products
Specific Regulator Warnings: {'compound': 'Melanotan / Melanotan II', 'warning': 'TGA (and FDA/MHRA internationally) have issued explicit safety warnings, particularly regarding changes to moles and skin-cancer surveillance risk. Not ARTG-registered.'}, {'compound': 'Unapproved injectable peptides (general)', 'warning': 'TGA consumer warning on contamination, infection, tissue damage, and mislabelled/code-only products.'}
Sport Anti Doping:
Body: Sport Integrity Australia (SIA) administers anti-doping in Australian sport, aligned with the World Anti-Doping Agency (WADA) Prohibited List.
Summary: Many peptides (growth hormone secretagogues/releasing peptides, GHRH analogues, TB-500/thymosin beta-4, IGF-1 analogues, HCG in males, etc.) are prohibited in sport at all times. Use by athletes carries anti-doping sanctions independent of TGA scheduling.
Source: https://www.sportintegrity.gov.au/what-we-do/anti-doping/substance-education/peptides
State Territory Note:
Principle: Scheduling is applied nationally via the Poisons Standard, but possession/supply offences and enforcement are administered under each state/territory's drugs-and-poisons legislation, so penalties and enforcement emphasis can differ by jurisdiction.
Examples: e.g. NSW Poisons and Therapeutic Goods Act; Victorian Drugs, Poisons and Controlled Substances Act; Queensland Medicines and Poisons Act. This dataset does not enumerate per-state penalties — consult the relevant state health department or legal counsel.
Factual Only: Listed as a structural fact; not sourcing guidance.
Testing Labs Referenced Publicly:
Note: Independent third-party purity/identity testing is discussed publicly in the peptide community. Named for factual completeness only; their inclusion is informational, NOT an endorsement, NOT a sourcing recommendation, and NOT geo-targeted.
Publicly Known Labs: Janoshik Analytical, Peptide Sciences / third-party HPLC-MS COA providers, Colmaric Analyticals
What A Coa Shows: A Certificate of Analysis typically reports identity (mass spec), purity (HPLC %), and sometimes endotoxin/sterility. Reading a COA: confirm the compound mass matches, purity figure, batch/lot, testing date, and that the COA is tied to the specific batch (not a generic marketing document).
Educational summary — verify against the primary regulator. Switch jurisdiction in the top bar to see others.
Most research peptides are not FDA-approved. Several (e.g. BPC-157) were placed in FDA Category 2 of the 503A bulk drug substances review (effectively excluded from compounding) in 2023. Approved peptide drugs (semaglutide, tirzepatide, bremelanotide, tesamorelin) are prescription medicines.
Educational summary — verify against the primary regulator. Switch jurisdiction in the top bar to see others.
Most research peptides have no MHRA marketing authorisation. Some compounds (e.g. melanotan II) have been subject to MHRA safety warnings. Approved peptide medicines are prescription-only.
Educational summary — verify against the primary regulator. Switch jurisdiction in the top bar to see others.
Sellers label unapproved peptides 'for research use only / not for human consumption' to position them outside therapeutic-goods regulation. It is a legal disclaimer, not a statement that the product is safe or that human use is endorsed. The product's identity, purity and sterility are not independently guaranteed by that label.
A Certificate of Analysis reports a batch's identity (usually by mass spectrometry) and purity (usually HPLC %, e.g. >98%), sometimes with endotoxin/sterility data. A meaningful COA is tied to the specific lot number, dated, from a named third-party lab, and the reported mass matches the claimed peptide. A generic, undated, or non-batch-specific document is a marketing artefact, not verification.
Independent purity/identity testing is discussed publicly in the peptide community; named labs include Janoshik Analytical and Colmaric Analyticals among third-party HPLC-MS providers. This is informational only and not an endorsement or sourcing recommendation.
Online 'research peptide' products are unregulated; the TGA explicitly warns that unapproved injectable peptides — especially code-only or unlabelled products — risk contamination, infection and tissue damage, and that quality/identity are not assured. This dataset does not provide sourcing guidance.
Reported considerations: generally well tolerated in animal studies, anecdotal: mild injection-site irritation, anecdotal: transient dizziness, nausea. The evidence base is largely preclinical (animal/in-vitro); published randomised human clinical trials are lacking or absent. Not approved for human use in AU, US, or UK. Sold internationally as a research chemical 'not for human consumption'. This is not a safety endorsement; safety data for unapproved compounds is incomplete.
Reported considerations: anecdotal: lethargy, head-rush after injection, limited safety data in humans. The evidence base is largely preclinical (animal/in-vitro); published randomised human clinical trials are lacking or absent. WADA-prohibited at all times. Not approved for human therapeutic use. This is not a safety endorsement; safety data for unapproved compounds is incomplete.
Reported considerations: topical: rare irritation, high topical concentrations may cause sensitivity. There is both human and animal/preclinical research, though the depth and quality vary by indication. Topical cosmetic use is legal in AU/US/UK. Injectable use is not approved. This is not a safety endorsement; safety data for unapproved compounds is incomplete.
Reported considerations: IV: flushing, chest tightness, nausea if infused too fast, injection-site discomfort. There is both human and animal/preclinical research, though the depth and quality vary by indication. Not an approved drug; offered as wellness IV therapy in some jurisdictions. Precursors (NMN/NR) sold as supplements (NMN status varies by country). This is not a safety endorsement; safety data for unapproved compounds is incomplete.
Reported considerations: nausea, vomiting, diarrhoea/constipation, rare: pancreatitis, gallbladder events, boxed warning: thyroid C-cell tumours (rodent). There is both human and animal/preclinical research, though the depth and quality vary by indication. FDA/TGA/MHRA-APPROVED prescription drug. Compounded/grey-market 'research' semaglutide is NOT the approved product and carries identity/purity risk. This is not a safety endorsement; safety data for unapproved compounds is incomplete.
Reported considerations: nausea, diarrhoea, decreased appetite, rare: pancreatitis, gallbladder events, thyroid C-cell warning (rodent). There is both human and animal/preclinical research, though the depth and quality vary by indication. FDA/TGA/MHRA-APPROVED prescription drug. Grey-market 'research' tirzepatide is not the approved product. This is not a safety endorsement; safety data for unapproved compounds is incomplete.
Reported considerations: GI: nausea, vomiting, diarrhoea (dose-related in trials), long-term safety unknown. There is both human and animal/preclinical research, though the depth and quality vary by indication. INVESTIGATIONAL ONLY. Not approved anywhere. Grey-market sale as 'research peptide' is unverified material. This is not a safety endorsement; safety data for unapproved compounds is incomplete.
Reported considerations: anecdotal: injection-site reaction, flushing, head-rush, water retention. There is both human and animal/preclinical research, though the depth and quality vary by indication. WADA-prohibited. Not approved for human therapeutic use. This is not a safety endorsement; safety data for unapproved compounds is incomplete.
Reported considerations: anecdotal: head-rush, flushing, mild headache, injection-site reaction. There is both human and animal/preclinical research, though the depth and quality vary by indication. WADA-prohibited. Not approved for human therapeutic use. This is not a safety endorsement; safety data for unapproved compounds is incomplete.
Reported considerations: limited human data, anecdotal: paradoxical alertness in some, headache. There is both human and animal/preclinical research, though the depth and quality vary by indication. Not approved for human use. Research peptide only. This is not a safety endorsement; safety data for unapproved compounds is incomplete.